<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta property="og:site_name" content="Vertex Pharmaceuticals" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://investors.vrtx.com/press-releases" />
<meta property="og:title" content="Press Releases | Vertex Pharmaceuticals" />
<meta property="og:description" content="The Investor Relations website contains information about Vertex Pharmaceuticals&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb74911/files/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://investors.vrtx.com/press-releases" />
<link rel="canonical" href="https://investors.vrtx.com/press-releases" />
<link rel="shortlink" href="https://investors.vrtx.com/node/5816" />

    <title>Press Releases | Vertex Pharmaceuticals</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_1HvT-90as-e3CXVWo_1w4S2XTy309NZf7XoB6NbSpLQ.css?delta=0&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_Irk1fXP27BWbV6Mh5txGirKi1dfzWYXgLu8LcVhc-H0.css?delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Arimo:400,400italic,700,300italic" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Poiret+One" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Josefin+Slab:400,700,600,300" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_WF_WjdFnydexFLH-q6EV4RnXpbWPAYGc92V0TcW0t5g.css?delta=5&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="print" href="/sites/g/files/knoqqb74911/files/css/css_BafFCdsxiUI1wldlRvpIN5iLHxcBJGqNdV_v3x4wwU4.css?delta=6&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_rnf9BGrG97ZF8sypxyVluZjd7arGQ8x7Upxx8ceBe3g.css?delta=7&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_zcZJg2ceexb8o86eQ2I6FQDMa0-CSF5vKxCHlcH4HzE.js?scope=header&amp;delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- OneTrust Cookies Consent Notice start for vrtx.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="55293c39-90c9-481e-be5a-a536e7236802" ></script>
<script type="text/javascript">
function OptanonWrapper() {
    var countryCode = OneTrust.getGeolocationData().country
    dataLayer.push({event:"GACountry", OneTrustCountryCode: countryCode})
}
</script>
<!-- OneTrust Cookies Consent Notice end for vrtx.com -->

<!-- Google Analytics Code -->
<script type="text/plain" class="optanon-category-C0002">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})
  (window,document,'script','//www.google-analytics.com/analytics.js','ga');
                                
  ga('create', 'UA-709045-2', 'auto');
  ga('send', 'pageview');
</script>

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-60HPP96Z4B" type="text/plain" class="optanon-category-C0002"></script>
<script type="text/plain" class="optanon-category-C0002"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-60HPP96Z4B'); </script> 


<!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://analytics.imirwin.com/js/container_rVlDBFll.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    

<a href="#skip-to-content" class="hide-txt">Skip to Content</a>

<div class="off-canvas-wrapper">

    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>

        <div class="off-canvas position-left reveal-for-large" id="my-info" data-off-canvas data-position="left">
            <div class="row column">
                <span class="logo">
                  <br>
                  <a href="//www.vrtx.com/">
                  <!-- animated logo -->
                   <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                  <br/>
                </span>

                <!-- nav -->
                <div class="row side-nav">
                    <div class="medium-8 medium-centered columns">
                        
    

<nav role="navigation" aria-labelledby="block-investorrelations-2-menu" class="block--system-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--system-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--e99e7083-5a42-4093-bf00-e1b8438402d1 block--e99e7083-5a42-4093-bf00-e1b8438402d1--5816 block block-menu navigation block-system-menublock menu--ir">
                        
    <h2 class="visually-hidden" id="block-investorrelations-2-menu">Investor Relations</h2>
    

                                            <ul data-block-uuid="e99e7083-5a42-4093-bf00-e1b8438402d1" class="vertical accordion-menu menu" data-accordion-menu>
                                        <li>
                <a href="/" target="" rel="" title="Main Investor Relations Page" data-drupal-link-system-path="&lt;front&gt;">Investors Home</a>
                            </li>
                                <li class="active-trail">
                <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/press-releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                            </li>
                                <li>
                <a href="/events-presentations" target="" rel="" data-drupal-link-system-path="node/24456">Events &amp; Presentations</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information" data-drupal-link-system-path="node/5916">Stock Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Quote &amp; Chart</a>
                            </li>
                                <li>
                <a href="/stock-information/historic-stock-lookup" data-drupal-link-system-path="node/5921">Historic Stock Lookup</a>
                            </li>
                                <li>
                <a href="/stock-information/investment-calculator" data-drupal-link-system-path="node/5926">Investment Calculator</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                            </li>
                                <li>
                <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/financial-information/quarterly-results" data-drupal-link-system-path="node/5986">Quarterly Results</a>
                            </li>
                                <li>
                <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">SEC Filings</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="http://www.vrtx.com/our-company/leadership">Leadership</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-company/leadership/#board-of-directors">Board of Directors</a>
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Governance Documents</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">IR Contacts</a>
                            </li>
                                <li>
                <a href="/investor-faqs" target="" rel="" data-drupal-link-system-path="node/5941">FAQs</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/medicines/our-approved-medicines">Approved Medicines</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-science/pipeline">Pipeline</a>
                            </li>
                                <li>
                <a href="/email-alerts" data-drupal-link-system-path="node/5946">Email Alerts</a>
                            </li>
                </ul>
    
                            </li>
                </ul>
    


    </nav>
<div id="block-stockquote-2" data-storage-id="node:31451:flexible_layout" class="block--market-data-block__stock-quote block--market-data-block__stock-quote--31451 block--sidebar-first--market-data-block__stock-quote block--sidebar-first--market-data-block__stock-quote--31451 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5--31451 block block-nir-market-data-block block-market-data-block__stock-quote">
  
    
      <div class='text-center'>
    <div class="quote-wrapper">
        <h5 class="text-center"></h5>
        <table class="stock-qupte">
            <tbody>
                                                                                                                                            <tr>
                    <td>Price</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Change</td>
                    <td></td>
                </tr>
                                                </tbody>
        </table>
    </div>
</div>
<div class="stock-time">
     - </div>
  </div>

<div id="block-stockinfoattributionthomsonreuters" class="block--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--31451 block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters--31451 block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc--31451 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters">
  
    
      <p>
  Data Provided by Refinitiv. Delayed ~15m.</p>

  </div>

<div id="block-widgetstockchart" class="block--nir-stock-chart block--nir-stock-chart--31451 block--sidebar-first--nir-stock-chart block--sidebar-first--nir-stock-chart--31451 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7--31451 block block-nir-stock-chart">
  
      <h2  id="block-nir-stock-chart">Nasdaq: VRTX</h2>
    
      
<img src="https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=VRTX.O-VRTX&scale=linear&duration=1yr&frequency=1dy&gridLine=n&bgColor=52247f&lineColor=ffffff&fillcolor=52247f|52247f&width=560&height=300&&amp;volume=0&amp;fontColor-C0=FFFFFF&amp;fontColor-C1=FFFFFF" width="560" height="300" ></img>

  </div>

                    </div>
                </div>

            </div>


                        <div class="stock text-center">
                  <div class="region region-sidebar-featured">
    <div id="block-shareholdertools-2" class="block--system-menu-blockshareholder-tools block--system-menu-blockshareholder-tools--31451 block--sidebar-featured--system-menu-block--shareholder-tools block--sidebar-featured--system-menu-block--shareholder-tools--31451 block--4121c46a-4fb3-40cf-a26e-3dc466a9248c block--4121c46a-4fb3-40cf-a26e-3dc466a9248c--31451 block block-system block-system-menu-blockshareholder-tools gcs-sidebar-block">
  
    
                    <ul data-block-uuid="4121c46a-4fb3-40cf-a26e-3dc466a9248c" class="tools">
          
                                              
        <li class="side-menu__item">
                    <a href="/email-alerts" title="Email Alerts" class="glyph-icon flaticon-alarm-1" target="">
            <span class="fa-stack">
            
                               <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/notifications.svg" alt="">
                
            </span>
          </a>

                  </li>
      
                                              
        <li class="side-menu__item">
                    <a href="/rss-news-feeds" title="RSS News Feeds" class="glyph-icon flaticon-newspaper" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/rss_feed.svg" alt="">

              
            </span>
          </a>

                  </li>
      
                                                
        <li class="side-menu__item">
                    <a href="/investor-feedback" title="Investor Feedback" class="glyph-icon flaticon-paper-plane" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/email.svg" alt="">
              
            </span>
          </a>

                  </li>
          </ul>
  


  </div>

  </div>

            </div>
            




        </div> <!-- /off-canvas -->

        <div class="off-canvas-content"  id="skip-to-content" data-off-canvas-content>

            <div class="title-bar hide-for-large">
                <div class="title-bar-left">
                    <button class="menu-icon" type="button" data-open="my-info" aria-label="Menu button"></button>
                    <span class="title-bar-title"><!-- Menu --></span>
                </div>
                <span class="logo">
                  <a href="//www.vrtx.com/">
                    <!-- static logo -->
                    <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                </span>
            </div>

            <div class="callout primary">
                <div class="row">
                    <h1 class="header-title">

                                            News & Events
                                        </h1>

                                    </div>
            </div>

            

            


                            <div id="ndq-content" class="row ndq-5816 inside-pages large-12 columns">
                    <h2 class="h2content-heading">

                                                    Press Releases
                                            </h2>



                      <div class="region region-content">
    <div id="block-nir-pid2172-websitenoticeblock" class="block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--dd8b7d55-3418-4333-8560-aa0535832f20 block--dd8b7d55-3418-4333-8560-aa0535832f20--5816 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2172-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--32fb46b7-e82f-437f-b00f-4734f5697096 block--32fb46b7-e82f-437f-b00f-4734f5697096--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
  
      <h1>
              Press Releases
          </h1>
    

  <div>
    
<div class="panel-display boxton clearfix " >

  <div class="container-fluid">
    <div class="row">
      <div class="columns large-12 radix-layouts-content panel-panel">
        <div class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7--5816 block block-nir-search block-search-form">
  
    
      <form data-block-uuid="69c1a507-53a5-47e3-8700-d9cecb7ecae7" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
        <input type="search" name="query" size="60" maxlength="128" placeholder="What are you looking for today?" class="form-search required" required="required" aria-required="true" />

        </div>
<input type="hidden" name="f[0]" value="type:nir_news" />
<input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit" />

</form>

  </div>

<div class="views-element-container block--views-blockwidget-news-table block--views-blockwidget-news-table--5816 block--contentmain--views-block--widget-news-table block--contentmain--views-block--widget-news-table--5816 block--c9e9f210-6659-4313-bbd1-f20963e32837 block--c9e9f210-6659-4313-bbd1-f20963e32837--5816 block block-views block-views-blockwidget-news-table">
  
    
      <div data-block-uuid="c9e9f210-6659-4313-bbd1-f20963e32837"><div class="view view-widget-news view-id-widget_news view-display-id-table js-view-dom-id-28e3fd45b55e80e4b0a9f9ceb5d7218c00aa9d7409bda1ba558962e62c656458">
  
    
      
      <div class="view-content">
      <table class="nirtable views-table views-view-table cols-3 collapse-table">
        <thead>
      <tr>
                                                  <th id="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date" scope="col"><a href="?items_per_page_toggle=1&amp;page=4&amp;order=field_nir_news_date&amp;sort=asc" title="sort by Date">Date</a></th>
                                                  <th id="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title" scope="col"><a href="?items_per_page_toggle=1&amp;page=4&amp;order=field_nir_news_title&amp;sort=asc" title="sort by Title and Summary">Title and Summary</a></th>
                                                  <th id="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format" scope="col">Additional Formats</th>
              </tr>
    </thead>
    <tbody>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-06-25T13:18:00Z" timezone="America/New_York" class="datetime">Jun 25, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-vertex-foundation-commit-4-million-support-racial" hreflang="en">Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Vertex Foundation Announces $1.5 Million Gift to Boston University’s New Center for Antiracist Research - -Biotechnology-focused curriculum established in partnership with Year Up- -Additional commitments made to STEAM education- BOSTON --(BUSINESS WIRE)--Jun.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-vertex-foundation-commit-4-million-support-racial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27536/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-06-12T16:00:00Z" timezone="America/New_York" class="datetime">Jun 12, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-new-clinical-data" hreflang="en">CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for CTX001 in transfusion-dependent beta thalassemia- -Sickle cell disease: Patient is free of vaso-occlusive crises at 9 months after CTX001 infusion-
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-new-clinical-data" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27531/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-06-10T07:00:00Z" timezone="America/New_York" class="datetime">Jun 10, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-1" hreflang="en">Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - KALYDECO ® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, in children as young as 6 months of age - LONDON --(BUSINESS WIRE)--Jun.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-1" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27526/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-06-03T14:02:00Z" timezone="America/New_York" class="datetime">Jun 3, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-diana-mckenzie-its-board-directors" hreflang="en">Vertex Appoints Diana McKenzie to its Board of Directors</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jun. 3, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Diana McKenzie has been appointed to its board of directors as an independent director. Ms. McKenzie is a senior technology leader and innovator with deep experience across pharma,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-diana-mckenzie-its-board-directors" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27466/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-05-14T13:04:00Z" timezone="America/New_York" class="datetime">May 14, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/new-data-investigational-crisprcas9-gene-editing-therapy" hreflang="en">New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  ZUG, Switzerland&amp;nbsp;and&amp;nbsp;CAMBRIDGE, Mass.&amp;nbsp;and&amp;nbsp;BOSTON,&amp;nbsp;May 14, 2020&amp;nbsp;(GLOBE NEWSWIRE) --&amp;nbsp; CRISPR Therapeutics &amp;nbsp;(Nasdaq: CRSP) and&amp;nbsp; Vertex Pharmaceuticals Incorporated &amp;nbsp;(Nasdaq: VRTX) today announced that new data from two ongoing Phase 1/2 clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001 in
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/new-data-investigational-crisprcas9-gene-editing-therapy" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27406/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-05-11T13:00:00Z" timezone="America/New_York" class="datetime">May 11, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-pharmaceuticals-announce-fda" hreflang="en">CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia ZUG, Switzerland&amp;nbsp;and&amp;nbsp;CAMBRIDGE, Mass.&amp;nbsp;and&amp;nbsp;BOSTON,&amp;nbsp;May 11,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-pharmaceuticals-announce-fda" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27391/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-05-01T07:00:00Z" timezone="America/New_York" class="datetime">May 1, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor-1" hreflang="en">Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - If approved, KALYDECO ® (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age - LONDON --(BUSINESS WIRE)--May 1, 2020-- Vertex
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor-1" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27301/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-04-29T20:01:00Z" timezone="America/New_York" class="datetime">Apr 29, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2020-financial-results" hreflang="en">Vertex Reports First-Quarter 2020 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Product revenues of $1.52 billion , a 77% increase compared to Q1 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.3 to $5.6 billion - BOSTON --(BUSINESS WIRE)--Apr. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2020-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27286/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-04-28T20:30:00Z" timezone="America/New_York" class="datetime">Apr 28, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-virtual-2020-annual-meeting-and-internet-access" hreflang="en">Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 28, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, due to public health and travel safety concerns related to the ongoing COVID-19 pandemic, its 2020 Annual Meeting of Shareholders will be held as a virtual meeting.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-virtual-2020-annual-meeting-and-internet-access" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27266/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-04-27T12:30:00Z" timezone="America/New_York" class="datetime">Apr 27, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-pharmaceuticals-and-affinia-therapeutics-establish-multi" hreflang="en">Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis BOSTON &amp;amp; WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 27, 2020-- Vertex Pharmaceuticals Incorporated
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-pharmaceuticals-and-affinia-therapeutics-establish-multi" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27246/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-04-24T11:00:00Z" timezone="America/New_York" class="datetime">Apr 24, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-foundation-announces-donation-food-banks-canada-help" hreflang="en">The Vertex Foundation Announces Donation to Food Banks Canada to Help With COVID-19 Response</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  TORONTO , April 24, 2020 /CNW/ - Vertex Pharmaceuticals Incorporated announced that the Vertex Foundation , a nonprofit charitable foundation, will donate $50,000 CAD to Food Banks Canada to support their COVID-19 Response Fund . Food banks across Canada have been severely impacted by COVID-19.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-foundation-announces-donation-food-banks-canada-help" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27236/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-04-21T06:00:00Z" timezone="America/New_York" class="datetime">Apr 21, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-innovative-reimbursement-agreement-switzerland" hreflang="en">Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland LONDON --(BUSINESS WIRE)--Apr. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-innovative-reimbursement-agreement-switzerland" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27226/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-04-20T12:30:00Z" timezone="America/New_York" class="datetime">Apr 20, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-first-quarter-2020-financial-results-april-29" hreflang="en">Vertex to Announce First-Quarter 2020 Financial Results on April 29</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 20, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2020 financial results on Wednesday, April 29, 2020 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-first-quarter-2020-financial-results-april-29" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27221/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-04-07T13:00:00Z" timezone="America/New_York" class="datetime">Apr 7, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-foundation-commits-5-million-support-global-covid-19" hreflang="en">The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 7, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-foundation-commits-5-million-support-global-covid-19" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27196/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-03-27T12:00:00Z" timezone="America/New_York" class="datetime">Mar 27, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-confirms-supply-chain-continuity-and-business-outlook-its" hreflang="en">Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Mar. 27, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today confirmed its 2020 business outlook and the continuity of the company’s supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its development programs given the ongoing
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-confirms-supply-chain-continuity-and-business-outlook-its" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27166/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-03-13T12:00:00Z" timezone="America/New_York" class="datetime">Mar 13, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-foundation-donates-500000-partners-healthcare-support" hreflang="en">The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare , a Boston -based nonprofit hospital and physician network, to support the needs of patients
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-foundation-donates-500000-partners-healthcare-support" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27161/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-03-09T13:52:00Z" timezone="America/New_York" class="datetime">Mar 9, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-confirms-supply-chain-continuity-and-2020-business" hreflang="en">Vertex Confirms Supply Chain Continuity and 2020 Business Outlook</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that the global coronavirus outbreak has not had any impact on the company’s supply chain or its 2020 business outlook. “The challenges facing the world with the spread of COVID-19 are significant, but it
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-confirms-supply-chain-continuity-and-2020-business" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27156/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-03-02T20:44:00Z" timezone="America/New_York" class="datetime">Mar 2, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-cancellation-its-march-3-presentation-cowen" hreflang="en">Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference . Following implementation of a companywide travel and meetings policy that is designed to reduce
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-cancellation-its-march-3-presentation-cowen" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27146/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-02-25T22:03:00Z" timezone="America/New_York" class="datetime">Feb 25, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-availability-cystic-fibrosis-medicine-kalydecor" hreflang="en">Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO ® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1 . Clinicians are able to apply for patient access using the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-availability-cystic-fibrosis-medicine-kalydecor" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27086/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-02-25T21:01:00Z" timezone="America/New_York" class="datetime">Feb 25, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-cowen-health-care-conference-march-3" hreflang="en">Vertex to Present at the Cowen Health Care Conference on March 3</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 a.m. ET . The audio portion of management&#039;s remarks will be available live through Vertex
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-cowen-health-care-conference-march-3" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27076/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-01-30T21:01:00Z" timezone="America/New_York" class="datetime">Jan 30, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2019-financial" hreflang="en">Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Full-year 2019 total GAAP product revenues of $4.16 billion - - Full-year 2019 total non-GAAP product revenues of $4.00 billion , a 32% increase compared to the full-year 2018 - - Company provides full-year 2020 total product revenue guidance of $5.1 billion to $5.3 billion - BOSTON --(BUSINESS
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2019-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26826/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-01-21T21:01:00Z" timezone="America/New_York" class="datetime">Jan 21, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-full-year-and-fourth-quarter-2019-financial" hreflang="en">Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-full-year-and-fourth-quarter-2019-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26786/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2020-01-08T21:01:00Z" timezone="America/New_York" class="datetime">Jan 8, 2020</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-13" hreflang="en">Vertex to Present at the J.P. Morgan Healthcare Conference on January 13</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 8, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management’s remarks can be accessed
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-13" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26746/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-12-13T18:55:00Z" timezone="America/New_York" class="datetime">Dec 13, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-republic-ireland-expand-long-term-cystic-fibrosis" hreflang="en">Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  LONDON --(BUSINESS WIRE)--Dec. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-republic-ireland-expand-long-term-cystic-fibrosis" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26726/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-12-10T11:57:00Z" timezone="America/New_York" class="datetime">Dec 10, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-0" hreflang="en">Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in children this young - LONDON --(BUSINESS WIRE)--Dec. 10, 2019-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26716/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-11-20T10:00:00Z" timezone="America/New_York" class="datetime">Nov 20, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/french-authorities-approve-national-reimbursement-orkambi" hreflang="en">French Authorities Approve National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  LONDON --(BUSINESS WIRE)--Nov. 20, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS ) have approved national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) for people ages two and older with
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/french-authorities-approve-national-reimbursement-orkambi" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26676/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-11-19T12:00:00Z" timezone="America/New_York" class="datetime">Nov 19, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-positive-safety-and" hreflang="en">CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta thalassemia: Patient is transfusion independent with total hemoglobin level of 11.9 g/dL
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-positive-safety-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27071/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-11-18T12:00:00Z" timezone="America/New_York" class="datetime">Nov 18, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-molecular-templates-establish-collaboration-discover" hreflang="en">Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019&amp;nbsp;-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-molecular-templates-establish-collaboration-discover" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/27141/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-11-13T11:29:00Z" timezone="America/New_York" class="datetime">Nov 13, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-confirms-wales-offer-accepted-access-all-licensed-cystic" hreflang="en">Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Eligible patients in Wales will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-confirms-wales-offer-accepted-access-all-licensed-cystic" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26616/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-11-12T15:51:00Z" timezone="America/New_York" class="datetime">Nov 12, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-confirms-northern-ireland-offer-accepted-cystic-fibrosis" hreflang="en">Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Eligible patients in Northern Ireland will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 12, 2019-- Vertex Pharmaceuticals Incorporated
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-confirms-northern-ireland-offer-accepted-cystic-fibrosis" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26611/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-11-07T21:01:00Z" timezone="America/New_York" class="datetime">Nov 7, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-12" hreflang="en">Vertex to Present at the Credit Suisse Healthcare Conference on November 12</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Nov. 7, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET . Management’s remarks will be available live through Vertex’s website at
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-12" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26601/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-31T16:15:00Z" timezone="America/New_York" class="datetime">Oct 31, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/phase-3-results-two-studies-trikafta" hreflang="en">Phase 3 Results from Two Studies of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Both studies met primary and all key secondary endpoints demonstrating significant improvements in lung function and other measures of the disease - - Results of both studies to be presented today at the 33rd Annual North American Cystic Fibrosis Conference as part of six presentations from
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/phase-3-results-two-studies-trikafta" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26551/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-31T11:21:00Z" timezone="America/New_York" class="datetime">Oct 31, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-medicines-agency-marketing" hreflang="en">Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations - LONDON --(BUSINESS WIRE)--Oct.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-medicines-agency-marketing" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26546/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-30T20:01:00Z" timezone="America/New_York" class="datetime">Oct 30, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2019-financial-results" hreflang="en">Vertex Reports Third-Quarter 2019 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Product revenues of $950 million , a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - BOSTON --(BUSINESS WIRE)--Oct. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2019-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26536/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-24T09:23:00Z" timezone="America/New_York" class="datetime">Oct 24, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-agreement-nhs-england-access-all-licensed" hreflang="en">Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Eligible patients in England will have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor)- LONDON --(BUSINESS WIRE)--Oct. 24, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an access agreement with
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-agreement-nhs-england-access-all-licensed" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26496/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-21T20:07:00Z" timezone="America/New_York" class="datetime">Oct 21, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-third-quarter-2019-financial-results-october-30" hreflang="en">Vertex to Announce Third-Quarter 2019 Financial Results on October 30</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-third-quarter-2019-financial-results-october-30" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26481/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-21T19:55:00Z" timezone="America/New_York" class="datetime">Oct 21, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/adding-multimedia-fda-approves-trikafta" hreflang="en">ADDING MULTIMEDIA FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/adding-multimedia-fda-approves-trikafta" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26491/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-21T19:55:00Z" timezone="America/New_York" class="datetime">Oct 21, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-trikafta-elexacaftortezacaftorivacaftor-and" hreflang="en">FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-trikafta-elexacaftortezacaftorivacaftor-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26471/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-21T17:26:00Z" timezone="America/New_York" class="datetime">Oct 21, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/spanish-government-approves-national-reimbursement-orkambir" hreflang="en">Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  LONDON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with KALYDECO ®
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/spanish-government-approves-national-reimbursement-orkambir" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26466/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-19T23:29:00Z" timezone="America/New_York" class="datetime">Oct 19, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-reimbursement-cystic-fibrosis-medicines" hreflang="en">Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  LONDON --(BUSINESS WIRE)--Oct. 19, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO ® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-reimbursement-cystic-fibrosis-medicines" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26461/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-18T12:37:00Z" timezone="America/New_York" class="datetime">Oct 18, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor-0" hreflang="en">Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - LONDON --(BUSINESS WIRE)--Oct. 18, 2019-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26456/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-10-01T12:00:00Z" timezone="America/New_York" class="datetime">Oct 1, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-carmen-bozic-md-new-chief-medical-officer-and" hreflang="en">Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
    BOSTON --(BUSINESS WIRE)--Oct. 1, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic , M.D., has been appointed as the company’s Executive Vice President, Global Medicines Development and Medical Affairs. Dr.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-carmen-bozic-md-new-chief-medical-officer-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26421/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-09-30T12:00:00Z" timezone="America/New_York" class="datetime">Sep 30, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-ribometrix-establish-strategic-collaboration-discover" hreflang="en">Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  &amp;nbsp; -Partnership will leverage Ribometrix’s discovery platform for up to three therapeutic programs- &amp;nbsp; &amp;nbsp; -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones and royalty payments- &amp;nbsp; &amp;nbsp; BOSTON &amp;amp; DURHAM, N.C. --(BUSINESS WIRE)--Sep.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-ribometrix-establish-strategic-collaboration-discover" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26416/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-09-12T08:06:00Z" timezone="America/New_York" class="datetime">Sep 12, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-new-access-agreement-scottish-government" hreflang="en">Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor LONDON --(BUSINESS WIRE)--Sep. 12, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that eligible cystic fibrosis
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-new-access-agreement-scottish-government" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26406/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-09-10T12:30:00Z" timezone="America/New_York" class="datetime">Sep 10, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-morgan-stanley-global-healthcare-conference-0" hreflang="en">Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Sep. 10, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET . The audio portion of management’s remarks can be accessed
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-morgan-stanley-global-healthcare-conference-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26401/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-09-03T12:00:00Z" timezone="America/New_York" class="datetime">Sep 3, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-acquire-semma-therapeutics-goal-developing-curative-cell" hreflang="en">Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired for $950 million in cash- BOSTON &amp;amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.
  </summary>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-acquire-semma-therapeutics-goal-developing-curative-cell" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26391/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-08-20T12:00:00Z" timezone="America/New_York" class="datetime">Aug 20, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-accepts-new-drug-application-vx-445-elexacaftor-tezacaftor" hreflang="en">FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020 - -Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-accepts-new-drug-application-vx-445-elexacaftor-tezacaftor" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26351/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-07-31T20:01:00Z" timezone="America/New_York" class="datetime">Jul 31, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2019-financial-results" hreflang="en">Vertex Reports Second-Quarter 2019 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Product revenues of $940 million , a 25% increase compared to 2018 - - Company increases full-year 2019 total product revenue guidance to $3.6 to $3.7 billion - - Company advancing programs in 5 additional diseases beyond cystic fibrosis - BOSTON --(BUSINESS WIRE)--Jul.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2019-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26306/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-07-25T12:00:00Z" timezone="America/New_York" class="datetime">Jul 25, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-dr-jeffrey-leiden-transition-role-executive" hreflang="en">Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jul. 25, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden , M.D., Ph.D, into the role of Executive Chairman of the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-dr-jeffrey-leiden-transition-role-executive" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26291/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-07-22T12:00:00Z" timezone="America/New_York" class="datetime">Jul 22, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-submits-new-drug-application-us-fda-triple-combination" hreflang="en">Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Application supported by positive results from two global Phase 3 studies in people with CF ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations- BOSTON --(BUSINESS WIRE)--Jul. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-submits-new-drug-application-us-fda-triple-combination" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26286/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
      </tbody>
</table>

    </div>
  
        <nav class="pager" role="navigation" aria-labelledby="pagination-heading">
    <h4 id="pagination-heading" class="visually-hidden">Pagination</h4>
    <ul class="pager__items js-pager__items">
                    <li class="pager__item pager__item--first">
          <a href="?items_per_page_toggle=1&amp;page=0" title="Go to first page">
            <span class="visually-hidden">First page</span>
            <span aria-hidden="true">First</span>
          </a>
        </li>
                          <li class="pager__item pager__item--previous">
          <a href="?items_per_page_toggle=1&amp;page=3" title="Go to previous page" rel="prev">
            <span class="visually-hidden">Previous page</span>
            <span aria-hidden="true">Previous</span>
          </a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=3" title="Go to page 4">
            <span class="visually-hidden">
              Page
            </span>4</a>
        </li>
              <li class="pager__item is-active">
                                          <a href="?items_per_page_toggle=1&amp;page=4" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>5</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=5" title="Go to page 6">
            <span class="visually-hidden">
              Page
            </span>6</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=6" title="Go to page 7">
            <span class="visually-hidden">
              Page
            </span>7</a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item pager__item--next">
          <a href="?items_per_page_toggle=1&amp;page=5" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">Next</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?items_per_page_toggle=1&amp;page=16" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true">Last</span>
          </a>
        </li>
          </ul>
  </nav>

  
          <div class="view-footer">
          <div class="results-summary">Displaying 201 - 250 of 836 results</div>
        </div>
    </div>
</div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                </div>
            

            


            <footer>
                                <div class="column footer-sitemap">
                    <div class="row small-up-1 medium-up-4 large-up-4 flexy">
                        

<div role="navigation" aria-labelledby="block-footercol1-menu" id="block-footercol1" class="block--system-menu-blockfooter-col-1 block--system-menu-blockfooter-col-1--5816 block--footer-first--system-menu-block--footer-col-1 block--footer-first--system-menu-block--footer-col-1--5816 block--da449755-c1be-4e93-bf75-4db21af16447 block--da449755-c1be-4e93-bf75-4db21af16447--5816 block block-menu navigation block-system-menublock menu--footer-col-1 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol1-menu" class="lead">Footer Col 1</p>
    

                              <ul data-block-uuid="da449755-c1be-4e93-bf75-4db21af16447" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Stock Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol2-menu" id="block-footercol2" class="block--system-menu-blockfooter-col-2 block--system-menu-blockfooter-col-2--31451 block--footer-first--system-menu-block--footer-col-2 block--footer-first--system-menu-block--footer-col-2--31451 block--bdf059f5-091d-492a-8531-746af0f478ff block--bdf059f5-091d-492a-8531-746af0f478ff--31451 block block-menu navigation block-system-menublock menu--footer-col-2 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol2-menu" class="lead">Footer Col 2</p>
    

                              <ul data-block-uuid="bdf059f5-091d-492a-8531-746af0f478ff" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol3-menu" id="block-footercol3" class="block--system-menu-blockfooter-col-3 block--system-menu-blockfooter-col-3--31451 block--footer-first--system-menu-block--footer-col-3 block--footer-first--system-menu-block--footer-col-3--31451 block--7e76016d-878b-43d2-a4f3-4289a342a22d block--7e76016d-878b-43d2-a4f3-4289a342a22d--31451 block block-menu navigation block-system-menublock menu--footer-col-3 small-6 large-3 columns">
            
    <p id="block-footercol3-menu" class="lead">Vertex Websites</p>
    

                              <ul data-block-uuid="7e76016d-878b-43d2-a4f3-4289a342a22d" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/">Global</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.fr/">France</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.de/">Germany</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.ca/">Canada</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtxpharma.co.uk/">United Kingdom</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/en-us">United States</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-socialmedia-menu" id="block-socialmedia" class="block--system-menu-blocksocial-media block--system-menu-blocksocial-media--31451 block--footer-first--system-menu-block--social-media block--footer-first--system-menu-block--social-media--31451 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1--31451 block block-menu navigation block-system-menublock menu--social-media small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-socialmedia-menu" class="lead">Social Media</p>
    

                              <ul data-block-uuid="5d1642a9-9f5b-4bed-9f56-6157a76875d1" class="menu vertical">
                                                                                              <li class="isSocialLink side-menu__item">
                            <a href="https://www.facebook.com/VertexPharmaInc" class="facebook" aria-label="facebook">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-facebook fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.linkedin.com/company/vertex-pharmaceuticals" class="linkedin" aria-label="linkedin">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-linkedin fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://twitter.com/VertexPharma" class="x-twitter" aria-label="x-twitter">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-x-twitter fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ/featured" class="youtube" aria-label="youtube">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-youtube fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
          </ul>
  


    </div>

                    </div>
                </div>
                                <div class="column primary footer-global">
                    <div class="row">
                                                <div class="medium-6 columns">
                                                        <div class="region region-footer">
                                <nav role="navigation" aria-labelledby="block-footerbottom-menu" class="block--system-menu-blockfooter-bottom block--system-menu-blockfooter-bottom--5986 block--footer--system-menu-block--footer-bottom block--footer--system-menu-block--footer-bottom--5986 block--e172c75d-9834-4259-9057-aa69edfb5161 block--e172c75d-9834-4259-9057-aa69edfb5161--5986 block block-menu navigation block-system-menublock menu--footer-bottom">
                                    <ul data-block-uuid="e172c75d-9834-4259-9057-aa69edfb5161" class="menu side-menu">
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/international-privacy" target="_blank">Privacy Policy</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/terms-and-conditions" target="_blank">Terms of Use</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <!-- OneTrust Cookies Settings button start -->
                                            <a id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</a>
                                            <!-- OneTrust Cookies Settings button end -->
                                        </li>
                                        <li>
                                            <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/images/privacyoptions.svg" style="width:25px">
                                        </li>
                                    </ul>
                                </nav>
                            </div>
                        </div>
                        
                        <div class="medium-6 columns">
                            <ul class="menu float-right">
                                <li class="menu-text">Copyright &copy; 2025</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </footer>


        </div> <!-- /off-canvas-content -->

        <div class="js-off-canvas-exit"></div>


    </div> <!-- /off-canvas-wrapper-inner -->
</div> <!-- /off-canvas-wrapper -->
  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","currentQuery":{"items_per_page_toggle":"1","page":"4"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyVUlFuwzAIvVAUa_3ZAXaCaQewiI06VhsqIG1z-zpOpa1TN22yhB_P8IzBTBonMAzcACVhG_gr5SJlAu1kOmAmF40ZvK2poIVP2EMq6AG9B8SpSDoEYCiLeVRw4n0TbjrvoP6ncItd-4fYisBRMUmtyI0n4V-1H7Ljmg6c_5Vj3uzrLH4rbS5OtTUHwr3bT4-w33q5ghE-4BIh55gKmEUoqL717kh59_S8C3JCVcqbdL9pe1X45m9VvKzwzZfS2tUzzjgZOUYWp9Qm9IAbb_ugkOkSCywyu4U7b7A2Bqxh_QnDifBsoduxSp4LXgFrIOEu","theme":"nir_pid2172","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"45e7a25462df2b241c7eec49f3c8a237acab787c5b520da38b10415af90811be"}}</script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery-2.1.4.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery.circliful.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/ndq-functions.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/foundation.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/vivus.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded-2.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.run.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_yoTi3ajw4iS9VMtHeeJMhx7zxXd9S5AacrChSDHVlFQ.js?scope=footer&amp;delta=9&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_GZWqVv5lmgvMD-78CCnz6GUVTpAe1Qj92_PpS3CTNZA.js?scope=footer&amp;delta=12&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- Adobe Omniture JS Rewrite -->
<script type="text/plain" class="optanon-category-C0004">var s_CCSWebHostingAccount = "trcgvertex";</script>
<script src="//assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" type="text/plain" class="optanon-category-C0004"></script>
  </body>
</html>
